ArticleIranian journal of pharmaceutical research : IJPR2015
Comparison of Different Crosslinking Methods for Preparation of Docetaxel-loaded Albumin Nanoparticles.
Article in Iranian journal of pharmaceutical research : IJPR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Are Aptamer-Based Biosensors the Future of the Detection of the Human Gut Microbiome?-A Systematic Review and Meta-Analysis.Biosensors · 2024Pooled it
- Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer.Acta pharmaceutica Sinica. B · 2026Review
- Development,Drug delivery · 2025Article
- Albumin Nanoparticles in Cancer Therapeutics: Clinical Status, Challenges, and Future Directions.Pharmaceutics · 2025Review
- Development of an Innovative Nanosystem Based on Functionalized Albumin and Oxidized Gellan for the Synergistic Delivery of Curcumin and Temozolomide in the Treatment of Brain Cancer.Gels (Basel, Switzerland) · 2025Article
- Enhancing bevacizumab efficacy in a colorectal tumor mice model using dextran-coated albumin nanoparticles.Drug delivery and translational research · 2025Article
- Periodate-Mediated Cross-Linking for the Preparation of Catechol Conjugated Albumin Nanoparticles Used for in Vitro Drug Delivery.ACS applied bio materials · 2025Article
- Preparation of stable and monodisperse paclitaxel-loaded bovine serum albumin nanoparticles via intermolecular disulfide crosslinking.Biochemistry and biophysics reports · 2024Article
- Albumin Nanoparticle-Based Drug Delivery Systems.International journal of nanomedicine · 2024Review
- Factors Affecting the Synthesis of Bovine Serum Albumin Nanoparticles Using the Desolvation Method.Nanotechnology, science and applications · 2024Review
- Translational Challenges and Prospective Solutions in the Implementation of Biomimetic Delivery Systems.Pharmaceutics · 2023Review
- Role of Chitosan-Loaded Solanine Glycoalkaloid fromTurkish journal of pharmaceutical sciences · 2023Article
- Dopamine-Conjugated Bovine Serum Albumin Nanoparticles Containing pH-Responsive Catechol-V(III) Coordination for In Vitro and In Vivo Drug Delivery.Biomacromolecules · 2023Article
- Maillard Reaction Crosslinked Alginate-Albumin Scaffolds for Enhanced Fenofibrate Delivery to the Retina: A Promising Strategy to Treat RPE-Related Dysfunction.Pharmaceutics · 2023Article
- Enhanced Targeted Delivery of Minocycline via Transferrin Conjugated Albumin Nanoparticle Improves Neuroprotection in a Blast Traumatic Brain Injury Model.Brain sciences · 2023Article
- Risk-Assessment-Based Optimization Favours the Development of Albumin Nanoparticles with Proper Characteristics Prior to Drug Loading.Pharmaceutics · 2022Article
- Article
- Microalgal Bioprocess Toward the Production of Microalgal Oil Loaded Bovine Serum Albumin Nanoparticles.The protein journal · 2021Article
- Effect of Cross-Linked Alginate/Oil Nanoemulsion Coating on Cracking and Quality Parameters of Sweet Cherries.Foods (Basel, Switzerland) · 2021Article
- Chitosan-Based Microparticles Enhance Ellagic Acid's Colon Targeting and Proapoptotic Activity.Pharmaceutics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last step of desolvation method for preparation of albumin nanoparticles, glutaraldehyde (GA) is added to stabilize the newly formed nanoparticles. Due to undesirable effects of GA, the objective of this study was to evaluate alternative methods of crosslinking including ultraviolet (UV) irradiation, adding of glucose and combination of both methods. The nanoparticles were prepared by desolvation procedure. Final particle size, zeta potential, FTIR, scanning electron micrograph, cellular uptake and cell toxicity of nanoparticles crosslinked with UV and/or glucose were compared with commonly crosslinked nanoparticles with GA. Moreover, drug release and stability parameters of docetaxel-loaded albumin nanoparticles were investigated. Size of all nanoparticles prepared by different methods was in the same range (100-200 nm). Zeta potential showed the same results except for those treated with UV. The results of FTIR assay were the same for all groups. Although crosslinking by UV or glucose alone resulted in cytotoxic effects, combination of UV and glucose had less cytotoxic effects compared to GA. Cellular uptake of nanoparticles crosslinked with UV + glucose and GA showed similar results. The release of docetaxel from UV + glucose and GA crosslinked nanoparticles showed the same biphasic release. These data support the idea that crosslinking with a combination of UV and glucose can be a promising alternative method for production of docetaxel-loaded albumin nanoparticles with the advantage of omitting toxic GA.
Indexed as
Identifiers
25901145PMC4403054W2136799184What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.